|Bid||911,000.00 x 0|
|Ask||911,000.00 x 0|
|Day's range||890,000.00 - 920,000.00|
|52-week range||624,000.00 - 948,000.00|
|Beta (5Y monthly)||0.85|
|PE ratio (TTM)||N/A|
|Earnings date||27 July 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||499,500.00|
Samsung Biologics (KRX: 207940.KS), one of the world's leading contract development and manufacturing organization (CDMO), signed a strategic partnership agreement with Kineta, Inc., a clinical-stage biotech company developing novel immunotherapies in oncology. Samsung Biologics will provide end-to-end CDMO service from cell line development, clinical drug substance, and drug product manufacturing services to support IND filing for KVA12.1, Kineta's novel anti-VISTA antibody in development for t
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company's policies for an enhanced ESG management system and related plans. The report focuses on the company's commitment to taking part in social responsibility over the past decade and its future plans for the next ten years and beyond.
Samsung Biologics, a global contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a real-time interactive platform to provide remote site inspections for both clients and regulatory agencies. The innovative digital solution was developed and implemented at Samsung Biologics a year ago in the wake of the pandemic and has since been successfully utilized in over 50 virtual regulatory and client audits and inspections and counting.